This update covers recommendations for glioblastoma; anaplastic astrocytoma, oligoastrocytoma and oligodendroglioma; and diffuse glioma.
Day One Biopharmaceuticals announced the recently completed submission of the rolling New Drug Application (NDA) to the FDA for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (LGG). The Company anticipates the FDA will file the rolling NDA by mid-November 2023.
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life.
Servier announced that the Phase III INDIGO clinical trial investigating AG 881 (vorasidenib) in monotherapy for patients with residual or recurrent IDH mutant low-grade glioma met its primary endpoint of progression free survival (PFS) and the key secondary endpoint of time to next intervention (TTNI). The results of the prespecified interim analysis were both statistically significant and clinically meaningful.
Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma (GBM).
Novartis announced the FDA granted approval for Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.
Novartis announced Tafinlar (dabrafenib) + Mekinist (trametinib) significantly improved efficacy in patients ages 1 to 17 years old with BRAF V600 pediatric low-grade glioma (pLGG) requiring first systemic treatment compared to chemotherapy, the current standard-of-care for these patients.
Tocagen announced that the Toca 5 Phase III, randomized, multi-center clinical trial evaluating Toca 511 & Toca FC in patients...
On 14 September 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Finlee, intended for the treatment of low and high grade glioma (LGG and HGG).